araag2/HINT huggingface dataset:
Clinical trial NCT00299104 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: folate, methotrexate, methylprednisolone, placebo, rituximab
SMILES: NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion criteria:

          -  Adult patients 18-80 years of age

          -  RA for ≥ 2 months;

          -  Receiving outpatient treatment

          -  Patients naive to, and considered to be candidates for, methotrexate treatment

        Exclusion criteria:

          -  Rheumatic autoimmune disease other than RA, or significant systemic involvement
             secondary to RA

          -  Inflammatory joint disease other than RA, or other systemic autoimmune disorder

          -  Diagnosis of juvenile rheumatoid arthritis, or RA before the age of 16

          -  Surgery within 12 weeks of study

          -  Previous treatment with any approved or investigational biologic agent for RA, an
             anti-alpha4-integrin antibody or co-stimulation modulator, or cell-depleting therapy

          -  Concurrent treatment with any biologic agent or DMARD other than methotrexate
Clinical trial NCT00113815 (phase 3, status: completed)
Conditions: partial seizure disorder, epilepsy, seizures
ICD codes: G40.001, G40.009, G40.011, G40.019, G40.101, G40.109, G40.111, G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801, G40.89, R56.1, F44.5, G40.501, G40.509, G40.111, G40.119
Drugs: topiramate, topiramate, topiramate, placebo
SMILES: [H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2, [H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2, [H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  1-24 months, inclusive

          -  Concurrent 1 or 2 antiepileptic drugs

          -  Receiving regular enteral feedings

          -  Weigh between 3.5 and 15 kg

          -  Clinical or EEG evidence of simple or complex POS

        Exclusion Criteria:

          -  Exclusively breast fed and cannot take medicine by mouth

          -  Surgically implanted and functioning vagus nerve stimulator

          -  Renal stones

          -  Medically uncontrolled illnesses or conditions

          -  Infantile seizures as a result of a correctable medical condition

          -  Progressive neurologic disorder
Clinical trial NCT00294385 (phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: docetaxel, gemcitabine, docetaxel, docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with histologic or cytologic diagnosis of breast cancer with evidence of
             unresectable, locally recurrent, or metastatic disease.

          -  Females, 18 to 75 years of age

          -  pre-treated with ONE anthracyclines containing chemotherapy either in
             neoadjuvant/adjuvant or 1st line metastatic setting will be enrolled into the study

          -  Patients with clinically measurable lesions will be enrolled in this study.
             Measurability is determined according to RECIST criteria

          -  Performance status of 70 or higher on the Karnofsky Performance Scale

          -  Adequate bone marrow reserve

          -  Adequate liver function

          -  Adequate renal function

          -  Informed consent form patient or guardian

          -  Childbearing potential either terminated by surgery, radiation, or menopause, use of
             an approved contraceptive method

        Exclusion Criteria:

          -  Active infection (at the discretion of the investigator).

          -  Known or suspected brain metastases requiring steroid or radiation treatment.

          -  Pregnancy (recent negative urine pregnancy test for pre-menopausal patients mandatory)

          -  Breast-feeding

          -  Serious concomitant systemic disorders incompatible with the study (at the discretion
             of the investigator).

          -  Second primary malignancy (except in situ carcinoma of the cervix or adequately
             treated basal cell carcinoma of the skin).

          -  Bone metastases, pleural effusion, or ascites as the only site of disease.

          -  Bone marrow transplantation or autologous stern cell infusion following high-dose
             chemotherapy for adjuvant or metastatic disease.
Clinical trial NCT01998906 (phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: trastuzumab, doxorubicin, paclitaxel, cmf
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  female patients, >=18 years of age, with locally advanced breast cancer.

        Exclusion Criteria:

          -  previous therapy for any invasive malignancy.
Clinical trial NCT00509106 (phase 3, status: completed)
Conditions: bacterial pneumonia
ICD codes: J15.9, P23.6
Drugs: ceftaroline fosamil for injection, ceftriaxone, placebo
SMILES: [H][C@]12SCC(SC3=NC(=CS3)C3=CC=[N+](C)C=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCC)\C1=NSC(NP(O)(O)=O)=N1)C([O-])=O, [H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Subjects with community-acquired pneumonia requiring:

          -  initial hospitalization or treatment in an emergency room or urgent care setting

          -  infection requiring initial treatment with IV antimicrobial

        Exclusion Criteria:

          -  Community-acquired pneumonia suitable for outpatient therapy with an oral
             antimicrobial agent

          -  Respiratory tract infections not due to community-acquired bacterial pathogens

          -  Infections resistant to ceftriaxone

          -  Any condition requiring concomitant systemic corticosteroids

          -  History of any hypersensitivity or allergic reaction to any ß-lactam antimicrobial
Clinical trial NCT00394589 (phase 3, status: terminated)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: infliximab increased frequency, infliximab increased dose, infliximab control
SMILES: CC1=CC(O)=CC(C)=C1Cl
Reason stopped: 
    study enrollment was stopped due to insufficient subject accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  aged 18 years or more

          -  with RA according to ACR criteria

          -  presented with a disease flare after initial response to infliximab, with both
             response and flare being defined using the DAS28 score (EULAR criteria)

          -  received the standard Remicade® dosing schedule per the EU label (3 mg/kg at Weeks 0,
             2, 6, [and 14])

          -  an initial response documented by moderate or good DAS28 improvement (EULAR criteria)
             from Week 0 to Week 6 or 14.

        Exclusion Criteria:

          -  a female who is, or intends to become, pregnant during or within 6 months of the end
             of the study, is nursing or not using adequate contraceptive measures

          -  has not observed the designated periods for concomitant medications

          -  used any investigational medical product within 30 days prior to Baseline

          -  any clinically significant deviation from normal in the physical examination or chest
             X-ray that in the investigator's judgment, may interfere with the study evaluation or
             affect subject safety

          -  rheumatic disease other than RA or has any systemic inflammatory condition with signs
             and symptoms that might confound the evaluations of safety and toxicity

          -  allergic reaction/sensitivity to the study drug or its excipients that requires
             corticosteroid pre-infusion medication.
Clinical trial NCT00095147 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: abatacept (aba) + methotrexate (mtx), double-blind (db), infliximab (inf) + mtx, db, placebo (pla) + mtx, db, pla + mtx switched to aba+ mtx, db, aba, open-label (ol)
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Rheumatoid Arthritis

          -  At least 3 months prior treatment with Methotrexate (MTX)

          -  At least 10 swollen joints and 12 tender joints and C-Reactive Protein of at least 1
             mg/dl

          -  Washout required for other disease modifying anti-rheumatic drugs (DMARDS)

        Exclusion Criteria:

          -  participants who have failed more than 3 DMARDs

          -  participants previously treated with an approved biologic drug

          -  History of cancer in the last 5 years

          -  Severe or recurrent bacterial infection

          -  Any previous or current medical conditions that are contraindications to the use of
             TNF blocking agents

          -  Women of Child Bearing Potential
Clinical trial NCT00439140 (phase 3, status: terminated)
Conditions: overactive bladder
ICD codes: N32.81
Drugs: normal saline (placebo)
SMILES: CC1=CC(O)=CC(C)=C1Cl
Reason stopped: 
    in agreement with fda the study was terminated based on data available.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Urinary incontinence as a result of neurogenic overactive bladder due to spinal cord
             injury or multiple sclerosis

          -  Inadequate response to anticholinergic medication used to treat overactive bladder.

          -  Neurological respiratory impairment and abnormal pulmonary function test results

        Exclusion Criteria:

          -  History or evidence of pelvic or urologic abnormality

          -  Previous or current diagnosis of bladder or prostate cancer

          -  Symptomatic or untreated urinary tract infection at time of enrollment
Clinical trial NCT00329446 (phase 3, status: completed)
Conditions: generalized anxiety disorder
ICD codes: F41.1
Drugs: quetiapine fumarate, escitalopram oxylate
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has a documented clinical diagnosis of Generalized Anxiety Disorder.

          -  Be able to understand and comply with the requirements of the study.

          -  Able to understand and provide written informed consent

        Exclusion Criteria:

          -  Patients (female) must not be pregnant or lactating

          -  Current or past diagnosis of stroke or transient ischemic attack (TIA).
Clinical trial NCT02053610 (phase 3, status: completed)
Conditions: lymphocytic leukemia, chronic
ICD codes: C91.11, C91.12, C91.10
Drugs: obinutuzumab, rituximab, chlorambucil
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl
Eligibility criteria:

        Inclusion Criteria:

          -  Adults >/=18 years

          -  Documented Cluster of Differentiation Antigen 20 (CD20) + B-Cell Chronic Lymphocytic
             Lymphoma (B-CLL)

          -  Previously untreated Chronic Lymphocytic Leukemia (CLL) requiring treatment according
             to the National Cancer Institute (NCI) criteria

          -  Total Cumulative Illness Rating Scale (CIRS) > 6 and/or creatinine clearance < 70
             ml/min.

        Exclusion Criteria:

          -  Prior CLL therapy

          -  Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's
             transformation)

          -  History of other malignancy unless the malignancy has been in remission without
             treatment for >/=2 years prior to enrolment, and except for carcinoma in situ of the
             cervix, basal or squamous cell skin cancer, surgically treated low-grade prostate
             cancer, or ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone

          -  Positive hepatitis serology (HBV, HCV) or positive HIV or Human T-Cell Leukemia Virus
             (HTLV) testing

          -  Patients with active infection requiring systemic treatment.
Clinical trial NCT00269386 (phase 3, status: completed)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: clarithromycin, placebo
SMILES: [H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with Crohn's disease diagnosed by conventional clinical, radiological and
             histological criteria.

          -  Active Crohn's disease: Crohn's Disease Activity Index (CDAI)> 200 and CRP > 10 mg/l.

          -  Patients on 10mg or less of prednisolone or 3mg budesonide.

          -  Patients on a stable dose of azathioprine for at least 3 months and on stable dose of
             5-ASA preparation for at least one month.

        Exclusion Criteria:

          -  Patients under 18 or unable to give informed consent.

          -  Patients on long term antibiotics for Crohn's disease or other indications

          -  Known sensitivity to clarithromycin

          -  Pregnant, post partum (<3months) or breast feeding females.

          -  Any change to medication for Crohn's disease for previous month.

          -  Patients with complications requiring surgery (significant intestinal obstruction,
             perforation or abscess)

          -  CDAI > 450

          -  Participation in other trials in the last 3 months.

          -  Serious intercurrent infection or other clinically important active disease (including
             renal and hepatic disease)

          -  Patients on cisapride, astemizole or terfenadine (prolonged QT interval and
             arrhythmias reported with macrolide antibiotics)
Clinical trial NCT00275236 (phase 3, status: completed)
Conditions: restless legs syndrome
ICD codes: G25.81
Drugs: rotigotine
SMILES: CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1
Eligibility criteria:

        Inclusion Criteria:

          -  Idiopathic RLS

        Exclusion Criteria:

          -  secondary RLS

          -  history of sleep disturbances

          -  symptomatic orthostatic hypotension
Clinical trial NCT00433836 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: valsartan, enalapril
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, ages 6-17, with a documented history of hypertension

          -  Must be able to swallow a pill

          -  Must be ≥ 18 kg or ≤160 kg

          -  MSSBP (mean of 3 measurements) must be ≥ 95th percentile, for age, gender and height,
             at Visit 2 (randomization), by office blood pressure measurement

          -  Patients who are eligible and able to participate in the study and whose
             parent(s)/guardian(s) consent in writing (written informed consent) to their doing so
             after the purpose and nature of the investigation has been clearly explained to them.
             (An assent will be required for some patients depending upon their age and local
             requirements regarding assents)

        Exclusion Criteria:

          -  Renal artery stenosis

          -  Current diagnosis of heart failure (NYHA Class II-IV).

          -  MSSBP ≥ 25% above the 95th percentile

          -  Second or third degree heart block without a pacemaker.

          -  Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia.

          -  Clinically significant valvular heart disease.

          -  Patient that demonstrates clinically significant ECG abnormalities other than those
             associated with left ventricular hypertrophy.

          -  Previous solid organ transplantation except renal, liver or heart transplantation.
             Renal, liver or heart transplant must have occurred at least 6 months prior to
             enrollment. Patient must be on stable doses of immunosuppressive therapy for 3 months
             and deemed clinically stable by the investigator.

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00375258 (phase 3, status: completed)
Conditions: hemorrhage
ICD codes: K94.01, K94.11, K94.21, K94.31, N99.510, H11.33, H35.63
Drugs: tranexamic acid, sodium chloride 0.9%
SMILES: NC[C@H]1CC[C@@H](CC1)C(O)=O, [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

        All trauma patients with ongoing significant haemorrhage (systolic blood pressure less than
        90 mmHg and/or heart rate more than 110 beats per minute), or who are considered to be at
        risk of significant haemorrhage, and are within 8 hours of the injury, are eligible for
        trial entry if they appear to be at least 16 years old. Although entry is allowed up to 8
        hours from injury, the earlier that patients can be treated the better.

        Exclusion Criteria:

        The fundamental eligibility criterion is the responsible doctor's 'uncertainty' as to
        whether or not to use an antifibrinolytic agent in a particular adult with traumatic
        haemorrhage. Patients for whom the responsible doctor considers there is a clear indication
        for antifibrinolytic therapy should not be randomised. Likewise, patients for whom there is
        considered to be a clear contraindication to antifibrinolytic therapy (such as, perhaps,
        those who have clinical evidence of a thrombotic disseminated intravascular coagulation)
        should not be randomised. Where the responsible doctor is substantially uncertain as to
        whether or not to use an antifibrinolytic, all these patients are eligible for
        randomisation and should be considered for the trial. There are no other pre-specified
        exclusion criteria
Clinical trial NCT00337675 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: montelukast sodium, comparator: placebo (unspecified), montelukast sodium
SMILES: [H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Patients aged 6 months to 5 years with episodic (periodic) asthma

        Exclusion Criteria:

          -  Patients who are not in otherwise good health

          -  Patients who have persistent asthma (continual asthma symptoms)
Clinical trial NCT01063764 (phase 3, status: completed)
Conditions: epilepsy, partial seizures
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801, G40.111, G40.119, G40.211, G40.219, G40.101, G40.109, G40.201
Drugs: levetiracetam
SMILES: CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  The patient has partial Epilepsy and the diagnosis must be confirmed in the last 6
             months

          -  The patients must be on a stable 1 or 2 anti-epileptic drug(s) treatment during the 4
             weeks prior to Baseline and must have at least 8 partial seizures during the 8-week
             prospective Baseline Period

          -  Patient at the age of 4 to 16 years, and at the body weight of 11 to 82 kg

        Exclusion Criteria:

          -  The patient has a treatable seizure etiology

          -  The patient has Epilepsy secondary to a progressive cerebral disease or any other
             progressively neurodegenerative disease, including Rasmussen and Landau-Kleffner
             diseases

          -  The patient has a history of status Epilepticus during the 3 months prior to Visit 1

          -  The patient has a past and present history of pseudo seizures

          -  The patient has a current diagnosis of Lennox-Gastaut syndrome
Clinical trial NCT00321113 (phase 3, status: completed)
Conditions: kidney transplantation
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: tacrolimus, mycophenolate mofetil, steroids
SMILES: COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patients minimum 60 years of age undergoing a cadaveric kidney
             transplant

          -  Patient has end stage kidney disease and is a suitable candidate for primary renal
             transplantation.

          -  Donors older than 60 years

          -  Female patients of child bearing age agree to practice effective birth control during
             the study.

          -  Patient has been fully informed and has given written informed consent

        Exclusion Criteria:

          -  Patient has significant, uncontrolled, concomitant infections and/or severe diarrhoea,
             vomiting, or active peptic ulcer

          -  Patient has previously received or is receiving an organ transplant other than kidney
             or a kidney retransplant

          -  Any pathology or medical condition that can interfere with this protocol study
             proposal

          -  Other exclusion criteria apply
Clinical trial NCT00368069 (phase 3, status: completed)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: keppra® extended release formulation - xr, placebo
SMILES: CC[C@H](N1CCCC1=O)C(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with a confirmed diagnosis of refractory epilepsy

          -  Patients must be receiving a stable dose of 1 - 3 concomitant Anti-Epileptic Drugs
             (AED)

          -  Female patients without childbearing potential. Female patients with childbearing
             potential are eligible if they use a medically accepted non-hormonal contraceptive
             method

        Exclusion Criteria:

          -  Seizures occurring in clusters

          -  Status epilepticus within 3 months of Visit 1

          -  History of non-epileptic seizures

          -  Known allergic reaction or intolerance to pyrrolidine derivatives and/or excipients

          -  Pregnant or lactating women. Any woman with childbearing potential who is not using a
             medically accepted, non-hormonal method of birth control